Efficacy and Safety of Dimethyl Fumarate Among Patients with Mild Cognitive Impairment and Dementia Due to Alzheimer's Disease

1. Men and women aged 55-90 years.

2. Patients diagnosed with mild cognitive impairment in Alzheimer's disease and mild to moderate Alzheimer's dementia (MMSE >16) diagnosed based on NIA-AA criteria.

3. MMSE score from 17 to 30 points.

4. CDR score from 0.5 to 2.

5. The patient signs an informed, voluntary consent to participate in the study.

6. The patient has a close person/de facto guardian who agrees to help the patient during participation in the study.

7. At least 6 years of education.

8. In the case of anti-Alzheimer's drugs, the use of cholinesterase inhibitors is permitted provided that they are included at least 3 months before entering the study and used at a stable dose for at least 60 days before entering the study. In the case of memantine, its use is permitted provided that it is included at least 4 months before entering the study and used at a stable dose for at least 3 months before entering the study

1. Lack of informed voluntary consent to participate in the study.

2. Patients who cannot read or write.

3. Pregnant, breastfeeding or childbearing women who do not use effective contraception (hormonal contraception, surgical sterilization, intrauterine device, condom in combination with vaginal spermicide).

4. Participation in another clinical trial, currently or within 3 months prior to the screening visit.

5. Liver failure (i.e. cirrhosis or active liver disease), diagnosed acute or chronic hepatitis regardless of cause.

6. Chronic kidney disease with GFR below < 60 ml/min/m2

7. Abnormal liver parameters: ALAT exceeding > 2 times the upper limit of normal

8. Leukopenia (<4000/mm3), granulocytopenia (<1500/mm3) or lymphopenia (<1000/mm3) regardless of the cause.

9. Severe agitation.

10. Mental retardation.

11. Delirium diagnosed according to DSM-5 criteria.

12. Diagnosis of neurological and neurodegenerative diseases other than Alzheimer's disease (multiple sclerosis, Parkinson's disease, Huntington's disease, previous stroke).

13. Presence of hemorrhagic foci in magnetic resonance imaging with a diameter of ≥ 2 cm3, more than three (3) ischemic stroke foci with a diameter of ≥ 1.5 cm3 or a single ischemic foci with a diameter of ≥ 2 cm3, presence of vascular malformations, aneurysms, subdural hematoma, normal pressure hydrocephalus, final decision at the discretion of the investigator.

14. Severe or uncontrolled somatic disease that could affect the course of the study (e.g. neoplastic, cardiovascular, respiratory, metabolic or digestive, severe renal failure, unstable type I or II diabetes, untreated or uncontrolled clinically significant hypertension).

15. Use of benzodiazepines or barbiturates within 1 week prior to screening.

16. Pharmacological immunosuppression.

17. Patients with bipolar disorder or psychotic disorders or any other psychiatric condition (current or past) that the Investigator believes interferes with the study.

18. Alcoholism or drug addiction as defined by DSM-5 within the past 5 years (dependent for more than 1 year and or in remission for less than 3 years).

19. Patients with any medical condition that, in the Investigator's judgment, is an exclusion criterion.

20. Thyroid hormone therapy initiated, discontinued, or modified within 3 months prior to screening visit.

21. Menopausal hormone replacement therapy initiated, discontinued, or modified within 3 months prior to screening visit.

22. Use of prohibited drugs in the study: Antineoplastic drugs (no studies). Immunosuppressive drugs (no studies). Corticosteroids (impact on project results). Live attenuated vaccines (no studies). Inactivated vaccines may be used. Benzodiazepines (impact on assessed endpoints). Other ethyl esters used orally or topically.